Cd80 variant immunomodulatory proteins and uses thereof
AssigneeAlpine Immune Sciences, Inc.
InventorsRyan SWANSON, Michael KORNACKER, Mark F. MAURER, Dan ARDOUREL, Daniel William DEMONTE, Joseph L. KUIJPER
Life of this patent
Estimating the term…
Abstract
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
Claims30
An engineered T cell, comprising a nucleic acid encoding a fusion protein of the formula CD80-linker-Fc, wherein CD80 is a variant CD80 polypeptide comprising the amino acid substitutions H18Y, A26E, E35D, M47L, V68M, A71G and D90G in the amino acid sequence set forth in SEQ ID NO:
- 2 or a portion thereof comprising the IgV domain, wherein the IgV domain is amino acids 35-141 of SEQ ID NO:1.
An engineered T cell, comprising:
- (i) a nucleic acid encoding a fusion protein of the formula CD80-linker-Fc, wherein CD80 is a variant CD80 polypeptide set forth in SEQ ID NO:2276, wherein a homodimer of the fusion protein is secretable from the engineered cell;
- and (ii) a chimeric antigen receptor (CAR).
An engineered T cell, comprising:
- (i) a nucleic acid encoding a fusion protein of the formula CD80-linker-Fc, wherein CD80 is a variant CD80 polypeptide set forth in SEQ ID NO:2276, wherein a homodimer of the fusion protein is secretable from the engineered cell;
- and (ii) an engineered T cell receptor (TCR).
Dependencies are inferred from the claim text.